Check out the companies making headlines in midday trading.
Johnson & Johnson — Shares of Johnson & Johnson fell 2.7% after the Centers for Disease Control and Prevention recommended Moderna and Pfizer vaccines for Covid-19 over the Johnson & Johnson vaccine on Thursday. The CDC confirmed 54 cases of people developing blood clots and showing low blood platelet levels after the Johnson & Johnson vaccine. Moderna shares gained 4.5%. Pfizer lost 2.9%, however, after it said it would amend its study with BioNTech of its Covid-19 vaccine in children between 6 months and under 5 years of age.
Cerner — The health-care information company's stock jumped 12.9% following new that it's in talks about a potential sale to Oracle. The deal could be worth $30 billion, according to the Wall Street Journal. Shares of Oracle fell 6.4%.
FedEx — Shares of the shipping company jumped 4.9% after quarterly earnings and revenue results topped expectations and it announced a $5 billion buyback. FedEx also reinstated its original 2022 EPS forecast.
Rivian Automotive — Electric vehicle maker Rivian saw shares fell 10.2% after reporting its first quarterly results as a public company and cut its 2021 vehicle production target, expecting to fall "a few hundred vehicles short" of its 1,200 vehicle target.
Darden Restaurants — Shares of the restaurant company slid 4.9% after CEO Gene Lee announced plans to retire on May 29. The Olive Garden parent earned $1.48 per share during the second quarter on $2.27 billion in revenue. Wall Street analysts were expecting the company to earn $1.43 per share on $2.23 billion in revenue, according to Refinitiv.
Winnebago — The camper added 0.8% after reporting a sizeable beat on the bottom line for its fiscal first quarter. Winnebago earned $3.51 per share, compared with FactSet's consensus estimate of $2.34 and revenue that also came in above analysts' forecasts.
Banks — Financial stocks were among the biggest laggards Friday as bond yields fell amid heightened fears about the omicron variant. Wells Fargo fell 4.6%. Goldman Sachs and Morgan Stanley lost 3.9$ and 3.1%, respectively. JPMorgan lost 2.2%.
Eli Lilly — Shares of the pharmaceutical company fell 4.1% after competitor Biogen's drug for Alzheimer's Disease received a negative opinion from European health regulators. Eli Lilly began the application process for approval of its own Alzheimer's drug in the U.S. in October and is expecting a regulatory decision next year. Goldman Sachs also initiated Eli Lilly stock as neutral with a $236 target, implying 15% downside.
— CNBC's Yun Li and Pippa Stevens contributed reporting.